Merck to face FDA adcomm in November over previously rejected potential chronic cough drug
The FDA announced this morning that on Nov. 17 it will hold an advisory committee meeting to take another look at Merck’s gefapixant for chronic …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
